Concourse Financial Group Securities, Inc. Erasca, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
227MCall Options Held
10.9KPut Options Held
65.1K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$29.7 Million2.92% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$25.6 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$24.8 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.4 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$19.1 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $187M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...